P and T最新文献

{"title":"Better.","authors":"David B Nash","doi":"10.32388/jy8n93","DOIUrl":"https://doi.org/10.32388/jy8n93","url":null,"abstract":"","PeriodicalId":38773,"journal":{"name":"P and T","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48340667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"American Society of Clinical Oncology","authors":"","doi":"10.32388/wgy03s","DOIUrl":"https://doi.org/10.32388/wgy03s","url":null,"abstract":"distinct and molecular subtypes lymphoma (DLBCL): (GCB) lymphoma, clinical and clinical trials identifying who in a high-risk Stomatitis occurs in approximately 65% of patients who are being treated with everolimus. Dr. Rugo’s meta-analysis of seven clinical trials looked at a total of 1,455 patients, 973 of whom developed stomatitis—89% within eight weeks of initiat-ing therapy. Forty percent of patients had a second onset of stomatitis. The dose of everolimus used in each of the seven trials was 10 mg/day. Bevacizumab targets vascular endothelial growth factor (VEGF)-blocking angiogenesis, and cetuximab blocks epider-mal growth factor receptor (EGFR), a protein affecting cancer growth and spread. Leukemia Oncology showed that for wild-type KRAS gene-mutated metastatic colorectal cancer patients, first-line treatment with and either of two targeted drugs, bevacizumab or cetuximab, led to similar median survival of about 29 months. re-analysis of a clinical trial taking into account the effect of large numbers of multiple myeloma patients switching to the more active treatment regimen the benefit shown in the original analysis.","PeriodicalId":38773,"journal":{"name":"P and T","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69642145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Ciprofloxacin in Combination With Beta-lactam Antibiotics a Recipe for Thrombocytosis?: A Case Report of Thrombocytosis in a Patient Receiving Ciprofloxacin and Ceftriaxone.","authors":"Ifeanyi Onor,&nbsp;Gabriela Andonie,&nbsp;Lynn Hoang,&nbsp;Taylor Smith,&nbsp;Shane Guillory,&nbsp;Seema Walvekar,&nbsp;Shane Sanne","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Thrombocytosis is defined as a platelet count greater than 400,000/mcL. We report the case of a patient who developed thrombocytosis after receiving ciprofloxacin and ceftriaxone therapy. A 73-year-old African-American female presented to the hospital with altered mental status attributed to sepsis and urinary tract infection. Patient was initiated on multiple empiric antibiotic therapy and was subsequently transitioned to ciprofloxacin and ceftriaxone at different times as definitive therapy for treatment of <i>Escherichia coli</i> bacteremia and <i>Escherichia coli</i> urinary tract infection. The patient developed thrombocytosis during and/or proximally to the administration of ciprofloxacin and ceftriaxone. A myeloproliferative source for the thrombocytosis was ruled out by the hematology/oncology team with a negative Janus kinase 2 V617F mutation assay result. In addition, other nondrug reactive sources of thrombocytosis (infection and anemia) were generally ruled out because the thrombocytosis was proximally linked with ciprofloxacin and ceftriaxone administration. The Naranjo Adverse Drug Reaction Probability Scale assigned a score of 5, indicating ciprofloxacin or ceftriaxone independently or in combination as a probable cause of thrombocytosis. This case report suggests that ciprofloxacin in combination with ceftriaxone (a beta-lactam antibiotic) may be a probable cause of thrombocytosis.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082235/pdf/nihms-1691210.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38949382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Inpatient Administration of Restricted Antineoplastic Medications at a Large Academic Medical Institution.","authors":"Kimberly M Lau,&nbsp;Katrina Derry,&nbsp;Ashley Dalton,&nbsp;Janine Martino","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Restricting oncology and hematology medications to outpatient infusion centers may be considered when infrequent administration is required, a low risk of serious adverse effects exists, or when prompt amelioration of a condition is not expected. At the University of California, San Diego (UCSD), we created a new formulary status for medications designated \"formulary, outpatient-restricted use only.\" This designation could optimize payer reimbursement, as well as improve patient comfort, by negating the need for inpatient admission. When the inpatient administration of a restricted medication is requested at UCSD, there ensues a loosely defined review process involving an informal conversation between the requesting prescriber and the oncology pharmacy and therapeutics (P&T) chair. Patient outcomes associated with this formulary status and informal request process are limited. The purpose of this study is to describe the use of formulary, outpatient-restricted oncology and hematology medications in the inpatient setting at a single-center, academic, and comprehensive cancer center.</p><p><strong>Methods: </strong>A retrospective chart review was conducted between January 1, 2015 and May 1, 2017. The primary outcome was to determine the percentage of formulary, outpatient-restricted oncology or hematology medications that were administered in the inpatient setting and continued to the outpatient setting. Secondary outcomes included overall survival, hospice enrollment, disease progression status, level of evidence supporting the medication usage, and cost.</p><p><strong>Results: </strong>Twenty-three patients and 24 outpatient-restricted medications met the inclusion criteria. Thirteen (54%) medications were continued upon discharge and eight (33%) were not continued in the outpatient setting. Five of those eight medications were discontinued as a result of patient death.</p><p><strong>Conclusion: </strong>In this single-center study, approximately one-third of the outpatient-restricted medications were not continued upon discharge. The findings suggest that our informal approval process could result in the suboptimal use of formulary outpatient-restricted medications for oncology and hematology indications. A more formalized request process might lead to the more effective utilization of these medications.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679954/pdf/ptj4408481.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41215270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perseris^TM: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.","authors":"Andrew Karas, Gary Burdge, Jose A Rey","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Perseris: A new, long-acting, atypical antipsychotic drug-delivery system.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679950/pdf/ptj4408460.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41215307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NIH Establishes Early Version of Personalized Medicine Platform.","authors":"Stephen Barlas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Will \"All of Us\" provide clues on the origins of various illnesses? Congress hopes that analyzing the medical and biological data of millions of people will boost precision medicine and help predict outcomes.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590921/pdf/ptj4407388.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37377953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accidental IV Infusion of Heparinized Irrigation in the Operating Room.","authors":"Matthew Grissinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Accidental IV administration of heparinized irrigation solution occurs frequently. Two cases from ISMP Canada offer some safe practice recommendations.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590924/pdf/ptj4407389.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37377957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digestive Disease Week 2019.","authors":"John Otrompke","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We review selected sessions on the questionable benefits of fecal microbiota transplant; intrahepatic cholestasis of pregnancy; weight-loss drugs in combination with intragastric balloon endoscopy; and beta blockers in pancreatic cancer.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590930/pdf/ptj4407428.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37377963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug and Device News.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Approvals, new indications and formulations, and safety issues.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590923/pdf/ptj4407392.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37377955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmaceutical Approval Update.","authors":"Mary Choy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Mavenclad (cladribine) tablets for relapsing MS forms; Duaklir Pressair (aclidinium bromide/formoterol fumarate) inhalant for COPD; Evenity (romosozumab-aqqg) injection for osteoporosis.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590926/pdf/ptj4407405.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37377958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}